European Medicines Agency recommends granting a marketing authorisation for filgrastim (Grastofil)

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product filgrastim (Grastofil), 30 MU/0.5 ml and 48 MU/0.5 ml, solution for injection or infusion intended for the treatment of neutropenia. Read more here.